Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Pharma
Bristol Myers CEO stays bullish on Cobenfy despite trial flop
While Cobenfy’s new-to-brand script growth appears to be moderating lately, BMS believes it will see strong uptake “in the back end of the year.”
Angus Liu
Jun 12, 2025 12:43pm
Teva forecasts $5B-plus in innovative drug sales by 2030
May 30, 2025 7:20am
BMS accentuates the positive after Cobenfy trial flop
Apr 24, 2025 11:31am
BMS' schizophrenia drug stumbles in blow to blockbuster plan
Apr 23, 2025 10:35am
Teva's subdued outlook puts damper on strong 2024 results
Jan 29, 2025 1:13pm
Lyndra enlists Thermo Fisher for research, manufacturing support
Jan 15, 2025 3:36pm
